{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:22:56Z","timestamp":1792423376324,"version":"4.5.0"},"reference-count":57,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Alpharma S.A. de C.V., Mexico City Sponsors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1111\/jcpt.12155","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T12:02:39Z","timestamp":1396612959000},"page":"368-375","source":"Crossref","is-referenced-by-count":17,"title":["Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine\/valproate exposure"],"prefix":"10.1155","volume":"39","author":[{"given":"S. J.","family":"Garc\u00e9s-Eisele","sequence":"first","affiliation":[{"name":"Cl\u00ednica Ruiz Laboratorios; Puebla M\u00e9xico"},{"name":"Universidad Popular Aut\u00f3noma del Estado de Puebla; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cedillo-Carvallo","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla de Bioequivalencia; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Reyes-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Ruiz Laboratorios; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Estrada-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla de Bioequivalencia; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"V\u00e1zquez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla de Bioequivalencia; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ju\u00e1rez-Calder\u00f3n","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla de Bioequivalencia; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Guzm\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Ruiz Laboratorios; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Due\u00f1as-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer; Instituto Nacional de Cancerolog\u00eda\/Instituto de Investigaciones Biom\u00e9dicas; UNAM; M\u00e9xico City M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruiz-Arg\u00fcelles","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Ruiz Laboratorios; Puebla M\u00e9xico"},{"name":"Laboratorios Cl\u00ednicos de Puebla de Bioequivalencia; Puebla M\u00e9xico"},{"name":"Universidad de las Am\u00e9ricas; Puebla M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"10.1111\/jcpt.12155-BIB0001|jcpt12155-cit-0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2013.00261","article-title":"Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy","volume":"3","author":"Jakopovic","year":"2013","journal-title":"Front Oncol"},{"key":"10.1111\/jcpt.12155-BIB0002|jcpt12155-cit-0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1111\/jcpt.12155-BIB0003|jcpt12155-cit-0003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"10.1111\/jcpt.12155-BIB0004|jcpt12155-cit-0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","article-title":"The epigenetic progenitor origin of human cancer","volume":"7","author":"Feinberg","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1111\/jcpt.12155-BIB0005|jcpt12155-cit-0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1111\/jcpt.12155-BIB0006|jcpt12155-cit-0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1111\/jcpt.12155-BIB0007|jcpt12155-cit-0007","first-page":"1596","article-title":"Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy","volume":"9","author":"Segura-Pacheco","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12155-BIB0008|jcpt12155-cit-0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2407-5-44","article-title":"A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes","volume":"5","author":"Zambrano","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1111\/jcpt.12155-BIB0009|jcpt12155-cit-0009","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-008-0773-z","article-title":"Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression","volume":"63","author":"Song","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/jcpt.12155-BIB0010|jcpt12155-cit-0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12155-BIB0011|jcpt12155-cit-0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-4-22","article-title":"Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study","volume":"4","author":"Ch\u00e1vez-Blanco","year":"2005","journal-title":"Mol Cancer"},{"key":"10.1111\/jcpt.12155-BIB0012|jcpt12155-cit-0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-4-55","article-title":"Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid","volume":"4","author":"Mora-Garc\u00eda","year":"2006","journal-title":"J Transl Med"},{"key":"10.1111\/jcpt.12155-BIB0013|jcpt12155-cit-0013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Due\u00f1as-Gonz\u00e1lez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/jcpt.12155-BIB0014|jcpt12155-cit-0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","article-title":"Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines","volume":"6","author":"Ch\u00e1vez-Blanco","year":"2006","journal-title":"Cancer Cell Int"},{"key":"10.1111\/jcpt.12155-BIB0015|jcpt12155-cit-0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.4049\/jimmunol.140.7.2197","article-title":"Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity","volume":"140","author":"Cornacchia","year":"1988","journal-title":"J Immunol"},{"key":"10.1111\/jcpt.12155-BIB0016|jcpt12155-cit-0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-4-32","article-title":"Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine","volume":"4","author":"Segura-Pacheco","year":"2006","journal-title":"J Transl Med"},{"key":"10.1111\/jcpt.12155-BIB0017|jcpt12155-cit-0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-061008-103102","article-title":"Epigenetics, DNA methylation, and chromatin modifying drugs","volume":"49","author":"Szyf","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jcpt.12155-BIB0018|jcpt12155-cit-0018","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/art.10833","article-title":"Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling","volume":"48","author":"Deng","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12155-BIB0019|jcpt12155-cit-0019","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/jcpt.12155-BIB0020|jcpt12155-cit-0020","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1111\/jcpt.12155-BIB0021|jcpt12155-cit-0021","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer","volume":"20","author":"Arce","year":"2006","journal-title":"PLoS One"},{"key":"10.1111\/jcpt.12155-BIB0022|jcpt12155-cit-0022","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5414\/CP201526","article-title":"Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype","volume":"49","author":"Gonz\u00e1lez-Fierro","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12155-BIB0023|jcpt12155-cit-0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06816-4","article-title":"N-acetylation pharmacogenetics","volume":"37","author":"Weber","year":"1985","journal-title":"Pharmacol Rev"},{"key":"10.1111\/jcpt.12155-BIB0024|jcpt12155-cit-0024","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0090-9556(25)06620-6","article-title":"Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine","volume":"23","author":"Lemke","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12155-BIB0025|jcpt12155-cit-0025","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2217\/14622416.9.11.1673","article-title":"Update on the pharmacogenetics of NATs: structural considerations","volume":"9","author":"Stanley","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12155-BIB0026|jcpt12155-cit-0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-398339-8.00005-7","article-title":"Arylamine N-acetyltransferases-from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention","volume":"63","author":"Sim","year":"2012","journal-title":"Adv Pharmacol"},{"key":"10.1111\/jcpt.12155-BIB0027|jcpt12155-cit-0027","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/17425250902877698","article-title":"N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine","volume":"5","author":"Hein","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/jcpt.12155-BIB0028|jcpt12155-cit-0028","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1124\/dmd.106.014621","article-title":"Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues","volume":"35","author":"Husain","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12155-BIB0029|jcpt12155-cit-0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FPC.0b013e3282f60db0","article-title":"Changes in consensus arylamine N-acetyltransferase gene nomenclature","volume":"18","author":"Hein","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12155-BIB0030|jcpt12155-cit-0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/hmg\/3.5.729","article-title":"Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes","volume":"3","author":"Hein","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1111\/jcpt.12155-BIB0031|jcpt12155-cit-0031","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14622416.3.3.349","article-title":"Arylamine N-acetyltransferases and drug response","volume":"3","author":"Meisel","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12155-BIB0032|jcpt12155-cit-0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14622416.3.1.19","article-title":"The pharmacogenetics of NAT: structural aspects","volume":"3","author":"Pompeo","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12155-BIB0033|jcpt12155-cit-0033","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":"Genetic polymorphism in N-Acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity","volume":"12","author":"Walker","year":"2009","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1111\/jcpt.12155-BIB0034|jcpt12155-cit-0034","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/jcpt.12155-BIB0035|jcpt12155-cit-0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","article-title":"Pharmacogenetics, drug-metabolizing enzymes, and clinical practice","volume":"58","author":"Gardiner","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1111\/jcpt.12155-BIB0036|jcpt12155-cit-0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2156-11-87","article-title":"Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations","volume":"11","author":"Talbot","year":"2010","journal-title":"BMC Genet"},{"key":"10.1111\/jcpt.12155-BIB0037|jcpt12155-cit-0037","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138920008784892155","article-title":"Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms","volume":"9","author":"Garc\u00eda-Mart\u00edn","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1111\/jcpt.12155-BIB0038|jcpt12155-cit-0038","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/carcin\/bgm085","article-title":"Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2","volume":"28","author":"Zang","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1111\/jcpt.12155-BIB0039|jcpt12155-cit-0039","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s004390100505","article-title":"Nomenclature for the description of human sequence variations","volume":"109","author":"Dunnen","year":"2001","journal-title":"Hum Genet"},{"key":"10.1111\/jcpt.12155-BIB0040|jcpt12155-cit-0040","unstructured":"SNP500Cancer Project Nomenclature for description of sequence variations http:\/\/www.wbcitation.org\/5YMNvyb1"},{"key":"10.1111\/jcpt.12155-BIB0041|jcpt12155-cit-0041","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1093\/nar\/17.10.3978","article-title":"Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation","volume":"17","author":"Grant","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.1111\/jcpt.12155-BIB0042|jcpt12155-cit-0042","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/pgs.11.122","article-title":"Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes","volume":"13","author":"Hein","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12155-BIB0043|jcpt12155-cit-0043","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/pgs.12.48","article-title":"Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations","volume":"13","author":"Suarez-Kurtz","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12155-BIB0044|jcpt12155-cit-0044","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jpba.2006.07.041","article-title":"Method development for dihydralazine with HPLC-MS\/MS - an old but tricky substance in human plasma","volume":"43","author":"Mascher","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1111\/jcpt.12155-BIB0045|jcpt12155-cit-0045","unstructured":"Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios Comisi\u00f3n de Control Anal\u00edtico y Ampliaci\u00f3n de Cobertura. Criterios para la validaci\u00f3n de m\u00e9todos fisicoqu\u00edmicos. June 2011 http:\/\/www.cofepris.gob.mx\/TyS\/Documents\/TercerosAutorizados\/cvfq032011.pdf"},{"key":"10.1111\/jcpt.12155-BIB0046|jcpt12155-cit-0046","unstructured":"NORMA Oficial Mexicana NOM-177-SSA1-1998 Que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los terceros autorizados que realicen las pruebas. May 1999 http:\/\/www.salud.gob.mx\/unidades\/cdi\/nom\/177ssa18.html"},{"key":"10.1111\/jcpt.12155-BIB0047|jcpt12155-cit-0047","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration Guidance for industry: bioanalytical method validation. May 2001 http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070107.pdf"},{"key":"10.1111\/jcpt.12155-BIB0048|jcpt12155-cit-0048","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","article-title":"Allelic discrimination using fluorogenic probes and the 5\u2019 nuclease assay","volume":"14","author":"Livak","year":"1999","journal-title":"Genet Anal"},{"key":"10.1111\/jcpt.12155-BIB0049|jcpt12155-cit-0049","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1743-422X-4-18","article-title":"The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study","volume":"4","author":"Cruz-Hern\u00e1ndez","year":"2007","journal-title":"Virol J"},{"key":"10.1111\/jcpt.12155-BIB0050|jcpt12155-cit-0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","article-title":"Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial","volume":"90","author":"Candelaria","year":"2011","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12155-BIB0051|jcpt12155-cit-0051","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1007\/s12032-010-9700-3","article-title":"A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results","volume":"28","author":"Coronel","year":"2011","journal-title":"Med Oncol"},{"key":"10.1111\/jcpt.12155-BIB0052|jcpt12155-cit-0052","doi-asserted-by":"crossref","first-page":"657579","DOI":"10.1155\/2010\/657579","article-title":"Response to hydralazine-valproate in a patient with mycosis fungoides","volume":"2010","author":"Due\u00f1as-Gonz\u00e1lez","year":"2010","journal-title":"Case Rep Med"},{"key":"10.1111\/jcpt.12155-BIB0053|jcpt12155-cit-0053","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2012.01.005","article-title":"Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia","volume":"12","author":"Cervera","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1111\/jcpt.12155-BIB0054|jcpt12155-cit-0054","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12155-BIB0055|jcpt12155-cit-0055","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/FPC.0b013e32834bec2b","article-title":"Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test","volume":"21","author":"Taja-Chayeb","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12155-BIB0056|jcpt12155-cit-0056","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","article-title":"The International HapMap Project","volume":"426","author":"International HapMap Consortium","year":"2003","journal-title":"Nature"},{"key":"10.1111\/jcpt.12155-BIB0057|jcpt12155-cit-0057","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/tpj.2012.29","article-title":"Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6","volume":"13","author":"Gonz\u00e1lez-Vacarezza","year":"2013","journal-title":"Pharmacogenomics J"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12155\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:42:54Z","timestamp":1746171774000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12155","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4,4]]}}}